Promoter Docon sells 9.90% stake in Thyrocare; holding drops to 51.02%

Promoter sold over 1%Ownership Changes View source PDF Explain this filing

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.2%Reaction day

₹643.05

prior close

₹615.40

announcement price

In-mkt

timing

Nifty Microcap 250market+0.2%-6.4% vs market

Healthcare Service Provider peers, median of 26sector+0.4%-6.7% vs sector

On the reaction day the stock moved 6.4 pts less than Nifty Microcap 250 and 6.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

-0.3

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.2+0.2-6.4+0.4-6.7

Next day

-2.8+0.2-3.1-2.1-0.8

-3.6+0.4-3.9-0.8-2.8

-5.1+0.7-5.9-0.9-4.2

-9.8+0.1-9.9-2.5-7.3

-11.8+0.7-12.5-1.0-10.8

-8.9+1.2-10.1-0.3-8.5

15d

-10.1+0.7-10.9-0.8-9.3

-14.8-1.2-13.6+0.0-14.8

-22.4-1.1-21.3-4.7-17.7

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Thyrocare promoter Docon Technologies sold 1,57,69,696 equity shares (about 9.90% of paid-up capital) via market trades on August 13, 2026. Promoter holding reduced from 60.92% to 51.02% of total paid-up equity share capital. Docon continues to remain a promoter and holding company of Thyrocare after the sale. Disclosure filed under SEBI LODR Regulation 30.

Likely market impact

Large promoter stake sale may weigh on the stock in the short term. Promoter still holds a majority at 51.02%, so no change of control.